Cargando…

Cell-Free RNA from Plasma in Patients with Neuroblastoma: Exploring the Technical and Clinical Potential

SIMPLE SUMMARY: Neuroblastoma mostly affects young children and despite intensive treatment, many children die of progressive disease. It remains challenging to identify those patients at risk. Analyzing blood, as liquid biopsies, is not invasive and can help to identify these patients. We studied w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lak, Nathalie S. M., Seijger, Anne, van Zogchel, Lieke M. J., Gelineau, Nina U., Javadi, Ahmad, Zappeij-Kannegieter, Lily, Bongiovanni, Laura, Andriessen, Anneloes, Stutterheim, Janine, van der Schoot, C. Ellen, de Bruin, Alain, Tytgat, Godelieve A. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10093559/ https://www.ncbi.nlm.nih.gov/pubmed/37046768 http://dx.doi.org/10.3390/cancers15072108

Ejemplares similares

Specific and Sensitive Detection of Neuroblastoma mRNA Markers by Multiplex RT-qPCR
por: van Zogchel, Lieke M. J., et al.
Publicado: (2021)

Improving Risk Stratification for Pediatric Patients with Rhabdomyosarcoma by Molecular Detection of Disseminated Disease
por: Lak, Nathalie S.M., et al.
Publicado: (2021)

Hypermethylated RASSF1A as Circulating Tumor DNA Marker for Disease Monitoring in Neuroblastoma
por: van Zogchel, Lieke M. J., et al.
Publicado: (2020)

Cell-Free DNA as a Diagnostic and Prognostic Biomarker in Pediatric Rhabdomyosarcoma
por: Lak, Nathalie S.M., et al.
Publicado: (2023)

Novel Circulating Hypermethylated RASSF1A ddPCR for Liquid Biopsies in Patients With Pediatric Solid Tumors
por: van Zogchel, Lieke M. J., et al.
Publicado: (2021)

Mesenchymal Neuroblastoma Cells Are Undetected by Current mRNA Marker Panels: The Development of a Specific Neuroblastoma Mesenchymal Minimal Residual Disease Panel
por: van Wezel, Esther M., et al.
Publicado: (2019)

The Metastatic Bone Marrow Niche in Neuroblastoma: Altered Phenotype and Function of Mesenchymal Stromal Cells
por: Hochheuser, Caroline, et al.
Publicado: (2020)

Targeted locus amplification to develop robust patient-specific assays for liquid biopsies in pediatric solid tumors
por: van Zogchel, Lieke M. J., et al.
Publicado: (2023)

Combining Hypermethylated RASSF1A Detection Using ddPCR with miR-371a-3p Testing: An Improved Panel of Liquid Biopsy Biomarkers for Testicular Germ Cell Tumor Patients
por: Lobo, João, et al.
Publicado: (2021)

CDC6: A novel canine tumour biomarker detected in circulating extracellular vesicles
por: Andriessen, Anneloes, et al.
Publicado: (2021)

Case series on clinical applications of liquid biopsy in pediatric solid tumors: towards improved diagnostics and disease monitoring
por: Gelineau, Nina U., et al.
Publicado: (2023)

The role of (131)I-metaiodobenzylguanidine (MIBG) therapy in unresectable and compromising localised neuroblastoma
por: Schoot, Reineke A., et al.
Publicado: (2013)

H2AFZ: A Novel Prognostic Marker in Canine Melanoma and a Predictive Marker for Resistance to CDK4/6 Inhibitor Treatment
por: Bongiovanni, Laura, et al.
Publicado: (2021)

Extracellular Vesicles: Novel Opportunities to Understand and Detect Neoplastic Diseases
por: Bongiovanni, Laura, et al.
Publicado: (2021)

G-CSF as a suitable alternative to GM-CSF to boost dinutuximab-mediated neutrophil cytotoxicity in neuroblastoma treatment
por: Martinez Sanz, Paula, et al.
Publicado: (2021)

Toxicity of upfront (131)I-metaiodobenzylguanidine ((131)I-MIBG) therapy in newly diagnosed neuroblastoma patients: a retrospective analysis
por: Bleeker, Gitta, et al.
Publicado: (2013)

Fenretinide induces mitochondrial ROS and inhibits the mitochondrial respiratory chain in neuroblastoma
por: Cuperus, Roos, et al.
Publicado: (2009)

Neuroblastoma and DIPG Organoid Coculture System for Personalized Assessment of Novel Anticancer Immunotherapies
por: M. Kholosy, Waleed, et al.
Publicado: (2021)

The Potential of Mesenchymal Stromal Cells in Neuroblastoma Therapy for Delivery of Anti-Cancer Agents and Hematopoietic Recovery
por: Hochheuser, Caroline, et al.
Publicado: (2021)

Mutational spectrum of ATRX aberrations in neuroblastoma and associated patient and tumor characteristics
por: van Gerven, Michael R., et al.
Publicado: (2022)

Response to: Correspondence on "G-CSF as a suitable alternative to GM-CSF to boost dinutuximab-mediated neutrophil cytotoxicity in neuroblastoma treatment" by Mora et al
por: Martinez Sanz, Paula, et al.
Publicado: (2021)

Mesenchymal Stromal Cells in Neuroblastoma: Exploring Crosstalk and Therapeutic Implications
por: Hochheuser, Caroline, et al.
Publicado: (2021)

123I‐MIBG scintigraphy and 18F‐FDG‐PET imaging for diagnosing neuroblastoma
por: Bleeker, Gitta, et al.
Publicado: (2015)

Nuclear Medicine Imaging in Neuroblastoma: Current Status and New Developments
por: Samim, Atia, et al.
Publicado: (2021)

Selective serotonin reuptake inhibitors (SSRIs) prevent meta-iodobenzylguanidine (MIBG) uptake in platelets without affecting neuroblastoma tumor uptake
por: Blom, Thomas, et al.
Publicado: (2020)

Treatment-Related Toxicities During Anti-GD2 Immunotherapy in High-Risk Neuroblastoma Patients
por: Blom, Thomas, et al.
Publicado: (2021)

Extracellular Vesicles: A New Source of Biomarkers in Pediatric Solid Tumors? A Systematic Review
por: Lak, Nathalie S. M., et al.
Publicado: (2022)

Thrombocytopenia after meta-iodobenzylguanidine (MIBG) therapy in neuroblastoma patients may be caused by selective MIBG uptake via the serotonin transporter located on megakaryocytes
por: Blom, Thomas, et al.
Publicado: (2021)

Urinary 3-Methoxytyramine Is a Biomarker for MYC Activity in Patients With Neuroblastoma
por: Verly, Iedan R. N., et al.
Publicado: (2022)

CD47-SIRPα Checkpoint Inhibition Enhances Neutrophil-Mediated Killing of Dinutuximab-Opsonized Neuroblastoma Cells
por: Martínez-Sanz, Paula, et al.
Publicado: (2021)

Anti-GD2 Based Immunotherapy Prevents Late Events in High-Risk Neuroblastoma Patients over 18 Months at Diagnosis
por: Tas, Michelle L., et al.
Publicado: (2021)

Chromosome 11q loss and MYCN amplification demonstrate synthetic lethality with checkpoint kinase 1 inhibition in neuroblastoma
por: Keller, Kaylee M., et al.
Publicado: (2022)

[(18)F]mFBG PET-CT for detection and localisation of neuroblastoma: a prospective pilot study
por: Samim, Atia, et al.
Publicado: (2022)

Correction to: [(18)F]mFBG PET‑CT for detection and localisation of neuroblastoma: a prospective pilot study
por: Samim, Atia, et al.
Publicado: (2023)

P366: ARE MINIMAL RESIDUAL DISEASE MEASUREMENTS AFTER CONSOLIDATION THERAPY USEFUL IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA?
por: Stutterheim, Janine, et al.
Publicado: (2023)

MEK inhibition causes BIM stabilization and increased sensitivity to BCL-2 family member inhibitors in RAS-MAPK-mutated neuroblastoma
por: Eleveld, Thomas F., et al.
Publicado: (2023)

Developmental Trajectories in Very Preterm Born Children Up to 8 Years: A Longitudinal Cohort Study
por: van Beek, Pauline E., et al.
Publicado: (2021)

A secondary role for hypoxia and HIF1 in the regulation of (IFNγ-induced) PD-L1 expression in melanoma
por: van Duijn, Anneloes, et al.
Publicado: (2021)

Technical Implications of the Chicken Embryo Chorioallantoic Membrane Assay to Elucidate Neuroblastoma Biology
por: Patiño-Morales, Carlos César, et al.
Publicado: (2023)

The Need for Special Education Among ELBW and SGA Preterm Children: A Cohort Study
por: van Beek, Pauline E., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_08j6n6d9n34ljcgu5e0qhq0i3c